Agenus Inc
AGEN3.840USD
+0.150+4.07%
收盘 11/06, 16:00（美东）报价延迟15分钟
115.22M总市值
亏损市盈率 TTM
关于 Agenus Inc 公司
Agenus Inc. 是一家免疫肿瘤学 (IO) 公司，专注于癌症和传染病，拥有一系列免疫药物。该公司专门开发激活人体免疫系统对抗癌症和感染的疗法。其产品线包括免疫调节抗体、过继细胞疗法（通过 MiNK Therapeutics, Inc.）和疫苗佐剂（通过 SaponiQx, Inc.）。其主要关注点是免疫肿瘤学，其多样化的产品线由其内部能力支持，包括现行良好生产规范 (cGMP) 制造和临床运营平台。其最先进的抗体候选药物是 botensilimab（一种多功能免疫细胞激活剂和人类 Fc 增强细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 阻断抗体 (AGEN1811)）和 balstilimab（一种程序性死亡受体-1 (PD-1) 阻断抗体）。其产品线包括几类免疫疗法：检查点抑制剂、免疫激活剂和肿瘤微环境调节剂。
Agenus Inc简介
公司代码AGEN
公司名称Agenus Inc
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
员工数量316
证券类型Ordinary Share
年结日Feb 04
公司地址3 Forbes Rd
城市LEXINGTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02421-7305
电话17816744400
网址https://agenusbio.com/
公司代码AGEN
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Agenus Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
地区USD
名称
营收
占比
United States
25.16M
97.95%
Rest of World
526.00K
2.05%
业务
地区
业务USD
名称
营收
占比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
股东统计
更新时间: 59 分钟前
更新时间: 59 分钟前
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.38%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.38%
股东类型
持股股东
占比
Investment Advisor
17.87%
Investment Advisor/Hedge Fund
4.62%
Research Firm
4.39%
Hedge Fund
2.84%
Individual Investor
1.76%
Venture Capital
0.19%
Family Office
0.17%
Bank and Trust
0.09%
其他
68.07%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
325
9.55M
29.96%
-3.46M
2025Q2
332
9.29M
33.90%
-3.65M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
2.53M
7.95%
-16.81K
-0.66%
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.34%
+564.25K
+112.85%
Jun 30, 2025
B. Riley Financial, Inc
756.96K
2.38%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
719.75K
2.26%
+350.35K
+94.84%
Jun 30, 2025
Millennium Management LLC
504.51K
1.58%
+504.51K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
489.68K
1.54%
-1.12M
-69.54%
Jun 30, 2025
Marshall Wace LLP
432.48K
1.36%
+432.48K
--
Jun 30, 2025
AQR Capital Management, LLC
430.88K
1.35%
-10.60K
-2.40%
Jun 30, 2025
BofA Global Research (US)
420.68K
1.32%
+220.33K
+109.97%
Jun 30, 2025
Armen (Garo H.)
338.69K
1.06%
+7.51K
+2.27%
Sep 19, 2025
查看更多
持股ETF
更新时间: 18 小时前
更新时间: 18 小时前
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0%
iShares Russell 3000 ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
